An 11-year-old girl from London has become the first UK patient to receive gene therapy for Bardet-Biedl syndrome, a rare genetic disorder that causes progressive blindness. Surgeons at St Helier Hospital injected healthy copies of the BBS10 gene directly into her retina in March, a procedure previously performed on only one other individual globally. The intervention is designed to stabilise or improve vision, offering a potential lifeline to patients who typically lose their sight by early adulthood.

The advance comes as gene-targeting therapeutics gain momentum across multiple diseases. In China, a six-patient phase I trial of RAG-17—an siRNA therapy for SOD1-related amyotrophic lateral sclerosis—showed that the drug was well tolerated and reduced key disease biomarkers, including a more-than-50% decline in cerebrospinal fluid SOD1 protein levels, according to data published in Nature Medicine. The investigational treatment, developed by Beijing Tiantan Hospital and Ractigen Therapeutics, is now moving into a larger clinical trial.

Families elsewhere are mobilising to bridge the gap between scientific promise and geographic or regulatory hurdles. In Brazil, the parents of a four-year-old with SPG50, a neurodegenerative condition affecting fewer than 100 people worldwide, are racing to raise about R$185,000 for experimental gene therapy in Dallas. In Australia, the family of a three-year-old diagnosed with diffuse intrinsic pontine glioma—an inoperable brain tumour—surpassed a A$400,000 fundraising target within days to secure a personalised mRNA vaccine manufactured in Canada, after missing a local trial’s eligibility window by weeks. Clinicians in both hemispheres stress that long-term data remain years away.

Beyond the experimental frontier, the week also brought reminders of the routine health hardships families confront. The actor Lauren Tom, known for the series Friends, disclosed that her 25-year-old daughter is battling osteosarcoma. Separately, authorities in Maryland are investigating a single-vehicle crash that killed 18-year-old actress Kaylee Hottle; her parents told US media they did not recognise the other occupants. For the families pursuing cutting-edge therapies, the next tangible milestones are regulatory decisions and early efficacy data from expanded trials, while researchers caution that durable results will require prolonged follow-up.